← Human Trials & Peer-Reviewed Studies
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control
Plain-language guide to PMID 18777156 (2009): crossover randomized controlled trial study of Insulin Aspart.
Key Facts
- PMID
- 18777156
- Journal
- Acta diabetologica
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Chisalita SI et al. (7 authors)
- DOI
- 10.1007/s00592-008-0055-6
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Aspart in this randomized controlled trial publication.
Their aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes.
Why It Was Studied
At the end of each treatment a 24-h metabolic profile was performed.
Similar 24-h blood glucose profiles were obtained with repaglinide and insulin aspart treatment.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Five patients, age 65.0+/-4.1 years (mean+/-SE), body weight 82.5+/-5.0 kg, BMI (body mass index) 27.7+/-1.5 kg/m(2) were treated for 10 weeks with repaglinide or insulin aspart in a randomized, cross-over study.
How the Study Was Run
The design is described as randomized and crossover.
The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.
Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.
A time span of 10 weeks appears in the methods.
Blood glucose, C-peptide, free human insulin, free total (human and analogue) insulin, proinsulin, IAPP, IGF-I, IGFBP-1 (IGF binding protein-1), GHBP (growth hormone binding protein) and plasma lipoprotein concentrations were measured.
What Was Measured
PubMed files the paper under topics including Apolipoproteins, Blood Glucose, C-Peptide, Carbamates, Cholesterol, Diabetes Mellitus, Type 2 and Hypoglycemic Agents.
What This Means in Plain Language
The paper is a randomized and crossover study of Insulin Aspart over 10 weeks.
The publication is from 2009 (Acta diabetologica), a journal based in Germany.
More context: the Insulin Aspart compound page, all human trials.
Our Notes on the Compound
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.